Patients and their caregivers are often left to navigate the confusing world of dementia by themselves, but Medicare is launching a new program to change that.

The approval of Eli Lilly's Kisunla provides a new option for patients in the early stages of the incurable, memory-destroying ailment.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.